Sunday - May 4, 2025
Atlanta, GA, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, announced today it has signed a contract with a partner for the use of RevID at a 350-bed medical center based in California. Through its automated charge reconciliation, RevID will contribute to improved revenue integrity and financial performance.
Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. RevID’s automated charge reconciliation ensures that providers can accurately capture, bill and ultimately be paid for all the care they provide.
“Our partners are entrusted with helping their clients improve operational and financial results, and we appreciate their faith in RevID’s ability to optimize charge capture at this medical center,” said Ben Stilwill, President, Streamline Health. “We look forward to accelerating the adoption of our unique, innovative solutions through our partners to help our nation’s healthcare providers receive accurate payment for the services they offer.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
To Learn More
Media
David Kosloski
Vice President, Marketing & Communications
651.308.1395
david.kosloski@streamlinehealth.net
Investors
Jacob Goldberger
Director, Investor Relations and FP&A
303.887.9625
jacob.goldberger@streamlinehealth.net
Last Trade: | US$3.06 |
Daily Change: | 0.10 3.39 |
Daily Volume: | 3,186 |
Market Cap: | US$13.070M |
May 01, 2025 January 22, 2025 December 18, 2024 December 16, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load